BioSpace News Archive

XPRIZE, the global leader in designing and operating world-changing incentive competitions, announces that it will offer a $1 million Moonshot Award in recognition of an XPRIZE team demonstrating the achievement of a “moonshot” technological feat outside the parameters or timeframe of an XPRIZE competition.

A new study published in the Journal of the American College of Cardiology has revealed that nearly half of non-elderly adults with atherosclerotic cardiovascular disease report financial hardship due to illness-related costs – and roughly one in five is unable to pay their medical bills.

Brad Vale, PhD, DVM General Partner at Strategic Healthcare Investment Partners, will join the board as part of the financing

BioConnect continues to be a leader in the physical security space and seeks to unify the world of physical and digital security through secure identity-based solutions.

Officials with the Aldrin Family Foundation announced one of the most significant contributors to the historic Moon landings, Northrop Grumman Corporation, has signed on as the title sponsor of the Apollo 50th Gala.

Edward Jones Earns 100 percent on Human Rights Campaign Foundation’s 17th Annual Scorecard on LGBTQ Workplace Equality

Integrated Workflow Combines NanoString’s GeoMx DSP High-Plex RNA Assays and Bio-Techne’s Highly Sensitive RNAscope Imaging Reagent Portfolio

Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma L.P., in conjunction with Mundipharma EDO GmbH, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its investigational drug tinostamustine, a potentially first-in-class alkylating deacetylase inhibiting molecule being studied in early phase clinical trials, for the treatment of T-cell prolymphocytic leukemia (T-PLL).

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced publication of abstracts on neratinib for the American Association for Cancer Research (AACR) Annual Meeting 2019.

Velicept Therapeutics, a privately-held specialty pharmaceutical company dedicated to the development of best-in-class compounds for the treatment of urological and gastrointestinal disorders, announced that its next generation beta-3 adrenoceptor agonist solabegron met the primary endpoint in VEL-2002, a Phase 2b study in patients with overactive bladder (OAB).